336 related articles for article (PubMed ID: 33098370)
1. Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma.
Han L; Shi H; Luo Y; Sun W; Li S; Zhang N; Jiang X; Gong Y; Xie C
Cancer Med; 2020 Dec; 9(24):9581-9594. PubMed ID: 33098370
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
3. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q
Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077
[TBL] [Abstract][Full Text] [Related]
4. CD8
Zhang M; Ma J; Guo Q; Ding S; Wang Y; Pu H
Front Immunol; 2022; 13():806877. PubMed ID: 35273597
[TBL] [Abstract][Full Text] [Related]
5. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
Mol Oncol; 2020 May; 14(5):917-932. PubMed ID: 32175651
[TBL] [Abstract][Full Text] [Related]
6. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
[TBL] [Abstract][Full Text] [Related]
7. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of the association between tumor-infiltrating immune cells and the prognosis of lung adenocarcinoma.
Pan Y; Sha Y; Wang H; Zhuang H; Ren X; Zhu X; Wei X
J Cancer Res Ther; 2020; 16(2):320-326. PubMed ID: 32474519
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
11. Prognostic signature of lung adenocarcinoma based on stem cell-related genes.
Huang Z; Shi M; Zhou H; Wang J; Zhang HJ; Shi J-
Sci Rep; 2021 Jan; 11(1):1687. PubMed ID: 33462260
[TBL] [Abstract][Full Text] [Related]
12. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
[TBL] [Abstract][Full Text] [Related]
13. An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma.
Han T; Liu Y; Wu J; Bai Y; Zhou J; Hu C; Zhang W; Guo J; Wang Q; Hu D
Sci Rep; 2023 Mar; 13(1):5153. PubMed ID: 36991102
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
[TBL] [Abstract][Full Text] [Related]
15.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
16. A Novel Nucleic Acid Sensing-related Genes Signature for Predicting Immunotherapy Efficacy and Prognosis of Lung Adenocarcinoma.
Peng X; Wu H; Zhang B; Xu C; Lang J
Curr Cancer Drug Targets; 2024; 24(4):425-444. PubMed ID: 37592781
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of microenvironment-related genes in lung adenocarcinoma.
Tao Y; Li Y; Liang B
Future Oncol; 2020 Aug; 16(24):1825-1837. PubMed ID: 32501723
[No Abstract] [Full Text] [Related]
18. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
19. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
[TBL] [Abstract][Full Text] [Related]
20. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.
Liao Y; He D; Wen F
Immunogenetics; 2021 Oct; 73(5):369-380. PubMed ID: 34302518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
